Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25.03
36.78
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Shenzhen Salubris Pharmaceuticals Co Ltd
Cash & Cash Equivalents
Shenzhen Salubris Pharmaceuticals Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
|
Cash & Cash Equivalents
¥916.1m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
6%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cash & Cash Equivalents
¥22.4B
|
CAGR 3-Years
74%
|
CAGR 5-Years
103%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Cash & Cash Equivalents
¥8.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cash & Cash Equivalents
¥22.3B
|
CAGR 3-Years
16%
|
CAGR 5-Years
41%
|
CAGR 10-Years
22%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cash & Cash Equivalents
¥14.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
24%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Cash & Cash Equivalents
¥391.7m
|
CAGR 3-Years
105%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shenzhen Salubris Pharmaceuticals Co Ltd
Glance View
Shenzhen Salubris Pharmaceuticals Co., Ltd. stands as a dynamic player in the pharmaceutical landscape, tracing its origins to China’s bustling hub of innovation, Shenzhen. From its inception, Salubris has steadily cultivated a robust portfolio, deeply rooted in the development, production, and commercialization of a wide array of pharmaceutical products. With a steadfast focus on cardiovascular and cerebrovascular medications, the company has adeptly positioned itself to meet significant medical needs, leveraging its expertise to produce both traditional and novel therapies. This focus is complemented by an ambitious expansion into biopharmaceuticals, a sector that holds significant potential for growth. Salubris thrives by combining its innovative R&D capabilities with efficient production processes, ensuring that its offerings not only reach a broad customer base but also adhere to stringent quality standards. The company’s business model revolves around a meticulously crafted combination of research innovation and strategic partnerships. By investing significantly in research and development, Salubris ensures a pipeline filled with promising drugs poised to address prevalent health issues. The company maximizes its revenues through its sales network, which extends beyond domestic borders, tapping into international markets where demand for high-quality pharmaceuticals continues to rise. Additionally, Salubris has been proactive in pursuing collaborations and partnerships, both to bolster its research capabilities and to navigate regulatory landscapes more effectively. By marrying these strategic approaches, Salubris not only sustains its competitive edge but also ensures a steady growth trajectory, embodying a business narrative that resonates with resilience and forward-thinking ambition.
See Also
What is Shenzhen Salubris Pharmaceuticals Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
916.1m
CNY
Based on the financial report for Sep 30, 2024, Shenzhen Salubris Pharmaceuticals Co Ltd's Cash & Cash Equivalents amounts to 916.1m CNY.
What is Shenzhen Salubris Pharmaceuticals Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
6%
Over the last year, the Cash & Cash Equivalents growth was -49%. The average annual Cash & Cash Equivalents growth rates for Shenzhen Salubris Pharmaceuticals Co Ltd have been -35% over the past three years , -3% over the past five years , and 6% over the past ten years .
You don't have any saved screeners yet
